To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.

The study will enroll 40~60 patients and complete 40 patients.

Inclusion Criteria:

• Subjects aged older than 20~75 years old.
• Able to sign informed consent prior to the study.
• The appearance of sputum and the difficulty of expectoration are both at level 2 or above.

Exclusion Criteria:

• Subjects with known hypersensitivity to Acetylcysteine preparations.
• Subjects with other serious medical diseases that are judged by the attending physician to affect the evaluation results (such as: tuberculosis, pneumonia, bronchial asthma, bronchiectasis, cor pulmonale, lung cancer, acute myocardial infarction, acute hepatitis, renal failure, etc.)
• Pregnancy or breast-feeding woman.
• Female subjects or their sexual partners do not use contraception during the trial.
• Joining any drug clinical trial within 3 months prior to dosing.
• Investigator considered to be inappropriate for enrollment.